semaglutide prediabetes weight loss diabetes prevention trial SELECT Trial: reduces the risk of MACE by 20% in people with overweight or obesity, pre-existing CVD, and no diabetes. Average of -9.4% at 51 months Semaglutide: Review and Place in

It occupies a niche almost nothing else does, it feeds the bacteria that produce butyrate, and in a human trial it raised GLP-1, a hormone central to appetite and blood sugar

Demirel t, N., Ko Yldrm, S., Erbac, E

Metformin Immediate-release dosing schedule Initial dose: 500 mg twice a day or 850 mg once a day Titration phase: Increase in 500 mg increments every week or 850 mg every 2 weeks Maintenance dose: 2000 mg/day (In divided doses) Maximum dose: 2550 mg/day Metformin Extended-release dosing schedule Initial dose: 500 to 1000 mg once a day Dose titration: Increase in 500 mg increments weekly according to the bodys tolerance Maximum dose: 2000 mg/day Semaglutide is most often given as a once-weekly injection, either as Ozempic or Wegovy

Moreover, the drug's tolerability was broadly in line with the current blockbuster

This aspect of GLP-1RAs can be of great benefit to those with psychiatric conditions who often have a higher risk of heart disease

Here's the uncomfortable truth: being "within range" and being optimized are two completely different things